RBC Capital Mkts slashes price target on Iterum Therapeutics plc [ITRM] – find out why.

Iterum Therapeutics plc [NASDAQ: ITRM] plunged by -$0.01 during the normal trading session on Monday and reaching a high of $0.53 during the day while it closed the day at $0.52.

Iterum Therapeutics plc stock has also loss -38.87% of its value over the past 7 days. However, ITRM stock has declined by -52.76% in the 3 months of the year. Over the past six months meanwhile, it has lost -84.21% and lost -88.45% year-on date.

The market cap for ITRM stock reached $19.99 million, with 21.24 million shares outstanding and 16.04 million shares in the current float. Compared to the average trading volume of 4.92M shares, ITRM reached a trading volume of 4621556 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Iterum Therapeutics plc [ITRM]:

RBC Capital Mkts have made an estimate for Iterum Therapeutics plc shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on June 02, 2020. The new note on the price target was released on January 21, 2020, representing the official price target for Iterum Therapeutics plc stock.

The Average True Range (ATR) for Iterum Therapeutics plc is set at 0.19

ITRM stock trade performance evaluation

Iterum Therapeutics plc [ITRM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -38.87. With this latest performance, ITRM shares dropped by -20.06% in over the last four-week period, additionally sinking by -84.21% over the last 6 months – not to mention a drop of -85.07% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ITRM stock in for the last two-week period is set at 36.68, with the RSI for the last a single of trading hit 31.62, and the three-weeks RSI is set at 39.17 for Iterum Therapeutics plc [ITRM]. The present Moving Average for the last 50 days of trading for this stock 0.7835, while it was recorded at 0.8650 for the last single week of trading, and 1.9185 for the last 200 days.

Iterum Therapeutics plc [ITRM]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Iterum Therapeutics plc [ITRM] shares currently have an operating margin of -275732.43. Iterum Therapeutics plc’s Net Margin is presently recorded at -278729.73.

Return on Total Capital for ITRM is now -254.31, given the latest momentum, and Return on Invested Capital for the company is -283.18. Return on Equity for this stock declined to -454.48, with Return on Assets sitting at -166.85.

Reflecting on the efficiency of the workforce at the company, Iterum Therapeutics plc [ITRM] managed to generate an average of -$2,343,864 per employee. Receivables Turnover for the company is 0.04 with a Total Asset Turnover recorded at a value of 0.00.Iterum Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.40 and a Current Ratio set at 0.40.

Earnings per share (EPS) analysis for Iterum Therapeutics plc [ITRM] stock

With the latest financial reports released by the company, Iterum Therapeutics plc posted -2.15/share EPS, while the average EPS was predicted by analysts to be reported at -1.65/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -30.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ITRM.

Iterum Therapeutics plc [ITRM]: Insider Ownership positions

There are presently around $3 million, or 40.20% of ITRM stock, in the hands of institutional investors. The top three institutional holders of ITRM stocks are: CANAAN PARTNERS X LLC with ownership of 1,733,170, which is approximately 0% of the company’s market cap and around 0.30% of the total institutional ownership; FRAZIER MANAGEMENT LLC, holding 1,538,316 shares of the stock with an approximate value of $0.8 million in ITRM stocks shares; and NEW LEAF VENTURE PARTNERS, L.L.C., currently with $0.76 million in ITRM stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Iterum Therapeutics plc stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 5 institutional holders increased their position in Iterum Therapeutics plc [NASDAQ:ITRM] by around 1,352,615 shares. Additionally, 11 investors decreased positions by around 2,241,836 shares, while 4 investors held positions by with 2,575,058 shares. The mentioned changes placed institutional holdings at 6,169,509 shares, according to the latest SEC report filing. ITRM stock had 5 new institutional investments in for a total of 1,352,615 shares, while 9 institutional investors sold positions of 2,236,387 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam